Urovant Sciences, Inc

83 articles with Urovant Sciences, Inc

• 

  Urovant's Irritable Bowel Drug Fails in Phase II; Genmab Abandons Cancer Drug

  11/25/2020

  Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.

• Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint

  11/24/2020

  Urovant Sciences (Nasdaq: UROV) today reported topline data from the Phase 2a randomized, double blind, placebo-controlled clinical trial evaluating once-daily vibegron 75 mg in women with abdominal pain due to irritable bowel syndrome (IBS) with IBS-D (diarrhea) and IBS-M (mixed IBS).

• Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study

  11/19/2020

  Urovant Sciences (Nasdaq: UROV) today announced positive efficacy and safety data from the vibegron EMPOWUR long term extension study with patient data over a total exposure of 52 weeks.

• 

  Sumitovant to Snap Up Development Partner Urovant Sciences

  11/16/2020

  In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma.

• Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares

  11/12/2020

  Urovant Sciences Shareholders to Receive $16.25 per share in cash Urovant Special Independent Committee of the Board Unanimously Recommends that all Shareholders Vote in Favor of the Transaction Agreement Represents Confidence in Urovant’s Future Success Transaction expected to be completed in Q1 2021, subject to approval by a majority of minority shareholders IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urova

• Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference

  11/10/2020

  Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 6:10 p.m. GMT (10:10 a.m. PST / 1:10 p.m. EST) on Tuesday, November 17, 2020, at the Jefferies Virtual London Healthcare Conference.

• Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results

  11/2/2020

  Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended September 30, 2020.

• Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results

  10/27/2020

  Urovant Sciences (Nasdaq: UROV) announced today that it will report financial results for its fiscal quarter ended September 30, 2020 after the close of U.S. financial markets on Monday, November 2, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s

• Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals

  10/7/2020

  Urovant Sciences (Nasdaq: UROV) today announced it has entered into a five-year U.S. co-promotion agreement with Sunovion Pharmaceuticals Inc. to promote vibegron in the primary care segment upon receiving U.S. Food and Drug Administration (FDA) approval for the drug.

• Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference

  9/8/2020

  Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2020, at the H.C. Wainwright & Co. Annual Global Investment Conference, which is being held virtually. A live, audio webcast for this event will be available on the Investor Relations sectio

• Urovant Sciences Reports Fiscal First Quarter 2020 Results

  8/13/2020

  Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020. The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its commercial and market access teams and completed enrollment in the Phase 2a study of vibegron for irritable bowel syndrome (IBS) pain.

• Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results

  8/6/2020

  Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s remarks. The con

• Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results

  6/18/2020

  Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020.

• Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals

  6/18/2020

  Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd. The co-promotion agreement will enable

• Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results

  6/11/2020

  Urovant Sciences (Nasdaq: UROV) announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial markets on Thursday, June 18, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s remarks. The conf

• Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market Access

  6/2/2020

  Walt Johnston is a proven senior pharmaceutical executive with nearly 30 years’ experience specializing in global strategy. He has extensive P&L experience in delivering significant revenue growth Mr. Johnston spent the last 12 years with Astellas Pharma, most recently as Senior Vice President, Urology and Hospital Business Unit. Prior to Astellas Pharma, he spent 18 years with Pfizer Kenton Stewart , a 30-year industry veteran, brin

• 

  BioSpace Movers & Shakers, May 29

  5/29/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Urovant Sciences Appoints James Hindman to Board of Directors

  5/27/2020

  James Hindman, a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to Actavis

• Urovant Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/26/2020

  Urovant Sciences announced that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020, at the Jefferies Healthcare Conference, which is being held virtually.

• Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting

  5/14/2020

  52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study ( NCT03583372 ) and data by age groups from the 12-week placebo-controlled EMPOWUR study ( NCT03492281 ) will be pr